Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBI-1301 NY-ESO-1 TCR-transduced autologous T cells in synovial sarcoma
jRCT1080223459Phase 2Completed
- Sponsor
- Takara Bio Inc.
- Start
- Feb 2017
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anti-NY-ESO-1 TCR-T in synovial sarcoma (SS), sponsored by Takara Bio Inc. Started Feb 2017; status: completed.
02
Drugs
anti-NY-ESO-1 TCR-T
03
Conditions
synovial sarcoma (SS)
Beyond the preview
Go deeper on jRCT1080223459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080223459.